Evaluating Human Breast Ductal Carcinomas with High-Resolution Magic-Angle Spinning Proton Magnetic Resonance Spectroscopy

Journal of Magnetic Resonance

Volumn 135, Issue 1, 1998, Pages 194-202

  Cheng, Leo Ling ^a,b   Chang, I Wen ^b   Smith, Barbara L ^a   Gonzalez, R Gilberto ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

High resolution magic angle spinning; Human breast ductal carcinomas; Intact tissue specimens; Metabolite diagnostic markers; Proton magnetic resonance spectroscopy

Indexed keywords

DIAGNOSTIC AGENT; LACTIC ACID; LIPID; PHOSPHORYLCHOLINE; PROTON; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMAGE ENHANCEMENT; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PAGET NIPPLE DISEASE; REPRODUCIBILITY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGE ENHANCEMENT; LACTIC ACID; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PHOSPHORYLCHOLINE; PROTONS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032209657     PISSN: 10907807     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmre.1998.1578     Document Type: Article

References (51)

1. D. Adler and R. Wahl, New methods for imaging the breast: Techniques, finding, and potential, Am. J. Roentgen. 164, 19-30 (1995).
2. K. Orang-Khadivi, B. Pierce, C. Ollom, L. Floyd, R. Siegle, and R. William, New magnetic resonance imaging techniques for the breast cancer, Breast Cancer Res. Treat. 32, 119-135 (1994).
3. C. Hoh, C. Schiepers, M. Seltzer, S. Gambhir, D. Silverman, J. Czernin, J. Maddahi, and M. Phelps, PET in oncology: Will it replace the other modalities? Semin. Nucl. Med. 27, 94-106 (1997).
4. P. Davis, M. Staiger, K. Harris, M. Ganott, J. Klementaviciene, J. McCarty, and H. Tobon, Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography, Breast Cancer Res. Treat. 37, 1-9 (1996).
5. H. Degani, V. Gusis, D. Weinstein, S. Fields, and S. Strano, Mapping pathophysiological features of breast tumors by MRI at high spatial resolution, Nat. Med. 3, 780-782 (1997).
6. M. Hall-Craggs and H. Mumtaz, Keeping abreast of magnetic resonance: Developments in breast cancer imaging [editorial], Clin. Radiol. 52, 253-255 (1997).
7. T. Helbich, A. Becherer, S. Trattnig, T. Leitha, P. Kelkar, M. Seifert, M. Gnant, A. Staudenherz, M. Rudas, G. Wolf, and G. Mostbeck, Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography, Radiology 202, 421-429 (1997).
8. S. Mussurakis, D. Buckley, and A. Horsman, Dynamic MR imaging of invasive breast cancer: correlation with tumour grade and other histological factors, Br. J. Radiol. 70, 446-451 (1997).
9. M. Sabel and H. Aichinger, Recent developments in breast imaging, Phys. Med. Biol. 41, 315-368 (1996).
10. S. Graham, M. Bronskill, J. Byng, M. Yaffe, and N. Boyd, Quantitative correlation of breast tissue parameters using magnetic resonance and X-ray mammography, Br. J. Cancer 73, 162-168 (1996).
11. E. Ranieri, M. D'Andrea, A. D'Alessio, S. Bergomi, G. Caprio, G. Calabrese, and F. Virno, Ultrasound in the detection of breast cancer associated with isolated clustered microcalcifications, mammographically identified, Anticancer Res. 17, 2831-2835 (1997).
12. F. Hall, Technologic advances in breast imaging. Current and future strategies, controversies, and opportunities, Surg. Oncol. Clin. N. Am. 6, 403-409 (1997).
13. S. Parker, T. Tong, S. Bolden, and P. Wingo, Cancer statistics, 1996, CA 46, 5-27 (1996).
14. C. Furnival, Breast cancer: Current issues in diagnosis and treatment, Aust. N. Z. J. Surg. 67, 47-58 (1997).
15. L. Tabar, P. Fagerberg, S. Duffy, N. Day, A. Gad, and O. Grontoff, Update of the Swedish two-county program of mammographic screening for breast cancer, Radiol. Clin. N. Am. 30, 187-210 (1992).
16. R. Bettelheim, K. Price, R. Gelber, B. Davis, M. Castiglione, A. Goldhirsch, and A. Neville, The International (Ludwig) Breast Cancer Study Group: Prognostic importance of occult axillary lymph node micrometastases from breast cancer, Lancet 335, 1565-1568 (1990).
17. M. Kaufmann, Review of known prognostic variables, Rec. Results Cancer Res. 140, 77-87 (1996).
18. M. Pack and R. Thomas, Axillary lymph node dissection: Does it have a role in primary breast cancer? Am. Surg. 62, 159-161 (1996).
19. B. Fisher, F. Perera, A. Cooke, A. Opeitum, V. Venkatesan, A. Dar, and L. Stitt, Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: alone: Patterns of recurrence, Int. J. Radiat. Oncol. Biol. Phys. 38, 541-550 (1997).
20. M. Shetty and J. Reiman HM, Tumor size and axillary metastasis, a correlative occurrence in 1244 cases of breast cancer between 1980 and 1995, Eur. J. Surg. Oncol. 23, 139-141 (1997).
21. J. Simpson and D. Page, The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer, Semin. Oncol. 23, 428-435 (1996).
22. C. Mountford, C. L. Lean, W. Mackinnon, and P. Russell, The use of proton MR in cancer pathology, in "Annual Report on NMR Spectroscopy" (G. Webb, Ed.) , pp. 173-215, Academic Press, London (1993).
23. D. Leibfritz, An introduction to the potential of 1H-, 31P- and 13C-NMR-spectroscopy, Anticancer Res. 16, 1317-1324 (1996).
24. J. de Certaines, High resolution nuclear magnetic resonance spectroscopy in clinical biology: application in oncology, Anticancer Res. 16, 1325-1332 (1996).
25. C. Mountford, C. Lean, R. Hancock, S. Dowd, W. Mackinnon, M. Tattersall, and P. Russell, Magnetic resonance spectroscopy detects cancer in draining lymph nodes, Invasion Metastasis 13, 57-71 (1993).
26. O. Kaplan, T. Kushnir, N. Askenazy, T. Knubovets, and G. Navon, Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment: 31P, 23Na, and 1H MRS studies of three models of pancreatic cancer, Cancer Res. 57, 1452-1459 (1997).
27. A. Kuesel, T. Kroft, J. Saunders, M. Prefontaine, N. Mikhael, and I. Smith, A simple procedure for obtaining high-quality NMR spectra of semiquantitative value from small tissue specimens: Cervical biopsies, Magn. Reson. Med. 27, 340-355 (1992).
28. P. Williams, J. Saunders, M. Dyne, C. E. Mountford, and K. Holmes, Application of a T2-filtered COSY experiment to identify the origin of slowly relaxing species in normal and malignant tissue, Magn. Reson. Med. 7, 463-471 (1988).
29. A. Kuesel, G. Sutherland, W. Halliday, and I. Smith, 1H MRS of high grade astrocytomas: mobile lipid accumulation in necrotic tissue, NMR Biomed. 7, 149-155 (1993).
30. A. Rutter, H. Hugenholtz, J. Saunders, and I. Smith, Classification of brain tumors by ex vivo 1H NMR spectroscopy, J. Neurochem. 64, 1655-1661 (1995).
31. R. Somorjai, B. Dolenko, A. Nikulin, N. Pizzi, G. Scarth, P. Zhilkin, W. Halliday, D. Fewer, N. Hill, I. Ross, M. West, I. Smith, S. Donnelly, A. Kuesel, and K. Briere, Classification of 1H MR spectra of human brain neoplasms: The influence of preprocessing and computerized consensus diagnosis on classification accuracy, J. Magn. Reson. Imaging 6, 437-444 (1996).
32. C. Lean, R. Newland, D. Ende, E. Bokey, I. Smith, and C. Mountford, Assessment of human colorectal biopsies by 1H MRS: Correlation with histopathology, Magn. Reson. Med. 30, 525-533 (1993).
33. P. Russell, C. Lean, L. Delbridge, G. May, S. Dowd, and M. CE, Proton magnetic resonance and human thyroid neoplasia. I: Discrimination between benign and malignant follicular thyroid neoplasmas by magnetic resonance spectroscopy, Am. J. Med. 96, 383-388 (1994).
34. L. Delbridge, C. Lean, P. Russell, G. May, S. Roman, S. Dowd, T. Reeve, and C. Mountford, Proton magnetic resonance and human thyroid neoplasia. II: Potential avoidance of surgery for benign follicular neoplasms, World J. Surg. 18, 512-517 (1994).
35. A. Fowler, A. Rappas, J. Holder, A. Finkbeiner, G. Dalrymple, M. Millins, J. Sprigg, and R. A. Komoroski, Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR, Magn. Reson. Med. 25, 140-147 (1992).
36. W. Mackinnon, P. Barry, P. Malycha, D. Gillett, P. Russell, C. Lean, S. Doran, B. Barraclough, M. Bilous, and C. Mountford, Fineneedle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy, Radiology 204, 661-666 (1997).
37. L. L. Cheng, I. W. Chang, D. A. Louis, and R. G. Gonzalez, Correlation of high resolution magic angle spinning proton MR spectroscopy with histopathology of intact human brain tumor specimens, Cancer Res. 58, 1825-1832 (1998).
38. L. L. Cheng, C. Lean, A. Bogdanova, J. Wright, SC, J. Ackerman, T. Brady, and L. Garrido, Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning, Magn. Reson. Med. 36, 653-658 (1996).
39. D. Moka, R. Vorreuther, H. Schicha, M. Spraul, E. Humpfer, M. Lipinski, P. Foxall, J. Nicholson, and J. Lindon, Magic angle spinning proton nuclear magnetic resonance spectroscopic analysis of intact kidney tissue samples, Anal. Commun. 34, 107-109 (1997).
40. K. Millis, W. Maas, D. Cory, and S. Singer, Gradient, high-resolution, magic-angle spinning nuclear magnetic resonance spectroscopy of human adipocyte tissue, Magn. Reson. Med. 38, 399-403 (1997).
41. P. Weybright, K. Millis, N. Campbell, D. G. Cory, and S. Singer, Gradient, high-resolution magic-angle spinning 1H nuclear magnetic resonance spectroscopy of intact cells, Magn. Reson. Med. 39, 337-344 (1998).
42. L. L. Cheng, M. Ma, L. Becerra, T. Ptak, I. Tracey, A. Lankner, and R. Gonzalez, Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy, Proc. Natl. Acad. Sci. USA 94, 6408-6413 (1997).
43. K. Herholz, W. Heindel, P. Luyten, J. den Hollander, U. Pietrzyk, J. Voges, H. Kugel, G. Friedmann, and W. Heiss, In vivo imaging of glucose consumption and lactate concentration in human gliomas, Ann. Neurol. 31, 319-327 (1992).
44. M. Preul, Z. Caramanos, D. Collins, J.-G. Villemure, R. Leblanc, A. Olivier, R. Pokrupa, and D. Arnold, Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy, Nature Med. 2, 323-325 (1996).
45. F. Podo and J. de Certaines, Magnetic resonance spectroscopy in cancer: Phospholipid, neutral lipid and lipoprotein metabolites and function, Anticancer Res. 16, 1305-1316 (1996).
46. H. Degani, Biological and physiological basis of breast MR, in "Proceedings of the International Society for Magnetic Resonance in Medicine 4th Scientific Meeting and Exhibition, New York, 1996," p. 333.
47. L. Le Moyec, R. Tatoud, M. Eugene, C. Gauville, I. Primot, D. Charlemagne, and F. Calvo, Cell and membrane lipid analysis by proton magnetic resonance spectroscopy in five breast cancer lines, Bri. J. Cancer 66, 623-628 (1992).
48. S. Singer, K. Souza, and W. Thilly, Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: A 13P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study, Cancer Res. 55, 5140-5145 (1995).
49. Y. Ting, D. Sherr, and H. Degani, Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells, Anticancer Res. 16, 1381-1388 (1996).
50. C. Elston and I. Ellis, "Systemic Pathology: The Breast," 3rd ed., Vol. 13, Churchill Livingstone, Edinburgh (1998).
51. D. Sze and O. Jardetzky, Determination of metabolite and nucleotide concentrations in proliferating lymphocytes by 1H-NMR of acid extracts, Biochim. Biophys. Acta 1054, 181-187 (1990).